CSL profits drop $3.7b as weak US vaccine rates hamper recovery

CSL Reports US$2.6 Billion Net Loss Amid Restructuring and Lower US Flu Vaccination Rates

Australian biotech giant CSL reported a 184 percent drop in net profit in the 2026 financial year, amid restructuring and lower flu vaccination rates in the United States. During the year, the company reported total revenue of US$15.8 billion (down 1 percent) and a net profit after tax and amortisation (NPATA) of US$3.1 billion (down 2 percent). However, one-off restructuring costs and impairments resulted in a net loss after tax of US$2.6 bill…

CSL profits drop $3.7b as weak US vaccine rates hamper recovery

The struggling healthcare giant reported a sharp drop in sales at its Vifor kidney business, but expects underlying earnings to increase 5 per cent this year.